Bullish Options Positioning in Gilead Sciences (GILD) Targets Upside in Shares Over the Coming Months -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences' (GILD) BIKTARVY Receives FDA Approval
February 7, 2018 2:11 PM ESTGilead Sciences' (NASDAQ: GILD) BIKTARVY Receives FDA Approval
From the FDA
New Drug Application (NDA): 210251
Company: GILEAD SCIENCES INC
Gilead Sciences (GILD) PT Lowered to $84 at Morgan Stanley
February 7, 2018 8:06 AM ESTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $87.00) while maintaining a Equalweight rating.
... MoreGilead Sciences (GILD) PT Lowered to $83 at Leerink Partners
February 7, 2018 7:10 AM ESTLeerink Partners lowered its price target on Gilead Sciences (NASDAQ: GILD) to $83.00 (from $86.00) while maintaining a Market Perform rating.
... MoreGilead Sciences (GILD) PT Raised to $80 at UBS
February 7, 2018 6:30 AM ESTUBS raised its price target on Gilead Sciences (NASDAQ: GILD) to $80.00 (from $77.00) while maintaining a Neutral rating.
... MoreGilead Sciences (GILD) PT Lowered to $90 at Deutsche Bank
February 7, 2018 6:02 AM ESTDeutsche Bank lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $91.00) while maintaining a Buy rating.
... MoreGilead Sciences (GILD) PT Raised to $105 at Citi
February 7, 2018 5:51 AM ESTCiti raised its price target on Gilead Sciences (NASDAQ: GILD) to $105.00 (from $103.00) while maintaining a Buy rating.
... MoreGilead Sciences (GILD) Raises Quarterly Dividend 9.6% to $0.57; 2.8% Yield
February 6, 2018 4:04 PM ESTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.57 per share, or $2.28 annualized. This is a 9.6% increase from the prior dividend of $0.52.
The dividend will be payable on March 29, 2018, to stockholders of record on March 16, 2018, with an ex-dividend date of March 15,... More
Gilead Sciences (GILD) Q4 Revenue Tops Views, Offers Guidance
February 6, 2018 4:03 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.74 billion.
GUIDANCE:
Gilead Sciences sees FY2018 revenue of $20-21 billion, versus the consensus of... More
